These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35086762)

  • 21. Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: A Systematic Review.
    Foerster R; Zwahlen DR; Buchali A; Tang H; Schroeder C; Windisch P; Vu E; Akbaba S; Bostel T; Sprave T; Zamboglou C; Zilli T; Stelmes JJ; Telkhade T; Murthy V
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33673077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Definitive Radiotherapy for Inoperable Stage IIB Non-small-cell Lung Cancer: Patterns of Care and Comparative Effectiveness.
    Jacobs CD; Gao J; Wang X; Clarke JM; Tong B; Ready NE; Suneja G; Kelsey CR; Torok JA
    Clin Lung Cancer; 2020 May; 21(3):238-246. PubMed ID: 31757764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer.
    King MT; Chen MH; Moran BJ; Braccioforte MH; Buzurovic I; Muralidhar V; Yang DD; Mouw KW; Devlin PM; D'Amico AV; Nguyen PL; Orio PF
    Urol Oncol; 2018 Apr; 36(4):157.e15-157.e20. PubMed ID: 29276060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereotactic body radiation therapy for prostate cancer-a review.
    Haque W; Butler EB; Teh BS
    Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S10. PubMed ID: 28917248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Outcomes of Stereotactic Body Radiotherapy With Immediate Versus Delayed Hormone Therapy in Men With Oligometastatic Recurrence of Prostate Cancer.
    Chaw CL; deSouza NM; Khoo V; Suh YE; van As N
    Clin Oncol (R Coll Radiol); 2020 Aug; 32(8):509-517. PubMed ID: 32423621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pilot study of intensity modulated radiation therapy with hypofractionated stereotactic body radiation therapy (SBRT) boost in the treatment of intermediate- to high-risk prostate cancer.
    Oermann EK; Slack RS; Hanscom HN; Lei S; Suy S; Park HU; Kim JS; Sherer BA; Collins BT; Satinsky AN; Harter KW; Batipps GP; Constantinople NL; Dejter SW; Maxted WC; Regan JB; Pahira JJ; McGeagh KG; Jha RC; Dawson NA; Dritschilo A; Lynch JH; Collins SP
    Technol Cancer Res Treat; 2010 Oct; 9(5):453-62. PubMed ID: 20815416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer : An investigation of 117 pelvic lymph nodes.
    Cozzi S; Botti A; Timon G; Blandino G; Najafi M; Manicone M; Bardoscia L; Ruggieri MP; Ciammella P; Iotti C
    Strahlenther Onkol; 2022 Aug; 198(8):700-709. PubMed ID: 34757443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT.
    Bouman-Wammes EW; van Dodewaard-De Jong JM; Dahele M; Cysouw MCF; Hoekstra OS; van Moorselaar RJA; Piet MAH; Verberne HJ; Bins AD; Verheul HMW; Slotman BJ; Oprea-Lager DE; Van den Eertwegh AJM
    Clin Genitourin Cancer; 2017 Oct; 15(5):e773-e782. PubMed ID: 28462855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stereotactic body radiotherapy for locally-advanced unresectable pancreatic cancer-patterns of care and overall survival.
    Dohopolski MJ; Glaser SM; Vargo JA; Balasubramani GK; Beriwal S
    J Gastrointest Oncol; 2017 Oct; 8(5):766-777. PubMed ID: 29184680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review.
    Keyes M; Merrick G; Frank SJ; Grimm P; Zelefsky MJ
    Brachytherapy; 2017; 16(2):245-265. PubMed ID: 28110898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stereotactic Radiotherapy for Lesions Detected via
    Pan J; Wei Y; Zhang T; Liu C; Hu X; Zhao J; Gan H; Liu W; Zhu B; Wu J; Wang B; Song S; Ye D; Zhu Y
    Eur Urol Oncol; 2022 Aug; 5(4):420-427. PubMed ID: 35304107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stereotactic body radiotherapy versus conventional radiotherapy for early-stage small cell lung cancer.
    Newman NB; Sherry AD; Byrne DW; Osmundson EC
    J Radiat Oncol; 2019 Jun; 8(2):239-248. PubMed ID: 31402969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.
    Yang DD; Mahal BA; Muralidhar V; Martin NE; Orio PF; Mouw KW; King MT; Choueiri TK; Trinh QD; Hoffman KE; Spratt DE; Feng FY; Nguyen PL
    Eur Urol; 2019 Jan; 75(1):35-41. PubMed ID: 30554605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk: early initiation of salvage therapy may replace long-term adjuvant androgen deprivation.
    Aizawa R; Takayama K; Nakamura K; Inoue T; Yamasaki T; Kobayashi T; Akamatsu S; Ogawa O; Mizowaki T
    Int J Clin Oncol; 2019 Oct; 24(10):1247-1255. PubMed ID: 31152322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing Treatment in Intermediate-Risk Prostate Cancer: Secondary Analysis of a Randomized Phase 3 Trial.
    Nabid A; Carrier N; Vigneault E; Van Nguyen T; Vavassis P; Brassard MA; Bahoric B; Archambault R; Vincent F; Bettahar R; Wilke D; Souhami L
    Int J Radiat Oncol Biol Phys; 2021 Nov; 111(3):732-740. PubMed ID: 33901566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.
    Rusthoven CG; Jones BL; Flaig TW; Crawford ED; Koshy M; Sher DJ; Mahmood U; Chen RC; Chapin BF; Kavanagh BD; Pugh TJ
    J Clin Oncol; 2016 Aug; 34(24):2835-42. PubMed ID: 27325855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer.
    Wu G; Baine MJ; Zhao N; Li S; Li X; Lin C
    BMC Cancer; 2019 Oct; 19(1):977. PubMed ID: 31640607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer.
    Johnson SB; Lester-Coll NH; Kelly JR; Kann BH; Yu JB; Nath SK
    Eur Urol; 2017 Nov; 72(5):738-744. PubMed ID: 28688613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-fraction prostate-specific membrane antigen positron emission tomography- and multiparametric magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer local recurrences.
    Ehret F; Hofmann T; Fürweger C; Kufeld M; Staehler M; Muacevic A; Haidenberger A
    BJU Int; 2023 Jan; 131(1):101-108. PubMed ID: 36114771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer.
    Fischer-Valuck BW; Rao YJ; Brenneman RJ; Patel PR; Filson CP; Jani AB; Liu Y; Goyal S; Xu K; Weiss A; Kucuk O; Cimmino C; Szabo S; Rossi P; Baumann BC; Pattaras J; Hershatter B; Patel SA
    Brachytherapy; 2020; 19(5):557-566. PubMed ID: 32624405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.